Role of masks, testing and contact tracing in preventing COVID-19 resurgences: a case study from New South Wales, Australia.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 04 2021
Historique:
entrez: 21 4 2021
pubmed: 22 4 2021
medline: 15 5 2021
Statut: epublish

Résumé

The early stages of the COVID-19 pandemic illustrated that SARS-CoV-2, the virus that causes the disease, has the potential to spread exponentially. Therefore, as long as a substantial proportion of the population remains susceptible to infection, the potential for new epidemic waves persists even in settings with low numbers of active COVID-19 infections, unless sufficient countermeasures are in place. We aim to quantify vulnerability to resurgences in COVID-19 transmission under variations in the levels of testing, tracing and mask usage. The Australian state of New South Wales (NSW), a setting with prolonged low transmission, high mobility, non-universal mask usage and a well-functioning test-and-trace system. None (simulation study). We find that the relative impact of masks is greatest when testing and tracing rates are lower and vice versa. Scenarios with very high testing rates (90% of people with symptoms, plus 90% of people with a known history of contact with a confirmed case) were estimated to lead to a robustly controlled epidemic. However, across comparable levels of mask uptake and contact tracing, the number of infections over this period was projected to be 2-3 times higher if the testing rate was 80% instead of 90%, 8-12 times higher if the testing rate was 65% or 30-50 times higher with a 50% testing rate. In reality, NSW diagnosed 254 locally acquired cases over this period, an outcome that had a moderate probability in the model (10%-18%) assuming low mask uptake (0%-25%), even in the presence of extremely high testing (90%) and near-perfect community contact tracing (75%-100%), and a considerably higher probability if testing or tracing were at lower levels. Our work suggests that testing, tracing and masks can all be effective means of controlling transmission. A multifaceted strategy that combines all three, alongside continued hygiene and distancing protocols, is likely to be the most robust means of controlling transmission of SARS-CoV-2.

Identifiants

pubmed: 33879491
pii: bmjopen-2020-045941
doi: 10.1136/bmjopen-2020-045941
pmc: PMC8061569
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e045941

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Emerg Infect Dis. 2020 Nov;26(11):2607-2616
pubmed: 32931726
BMC Infect Dis. 2022 Mar 7;22(1):232
pubmed: 35255823
J Epidemiol Community Health. 2020 Oct;74(10):861-866
pubmed: 32576605
Wellcome Open Res. 2020 Apr 9;5:67
pubmed: 32685698
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
J Travel Med. 2021 Feb 23;28(2):
pubmed: 32946584
Nature. 2020 Aug;584(7820):262-267
pubmed: 32512578
Science. 2020 Jul 10;369(6500):
pubmed: 32414780
Lancet Public Health. 2020 Aug;5(8):e452-e459
pubmed: 32682487
Lancet Microbe. 2020 May;1(1):e10
pubmed: 32835322
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
J Med Virol. 2021 Feb;93(2):820-830
pubmed: 32691881
Nat Hum Behav. 2020 Dec;4(12):1303-1312
pubmed: 33199859
PLoS Comput Biol. 2021 Jul 26;17(7):e1009149
pubmed: 34310589
Lancet Infect Dis. 2020 Oct;20(10):1151-1160
pubmed: 32559451
Science. 2020 May 15;368(6492):742-746
pubmed: 32269067
BMJ. 2020 Sep 9;370:m3410
pubmed: 32909958
Lancet Microbe. 2021 Jan;2(1):e1
pubmed: 33521732
Nat Commun. 2021 May 20;12(1):2993
pubmed: 34017008
Asia Pac J Public Health. 2020 May;32(4):161-162
pubmed: 32429676
Science. 2020 May 8;368(6491):
pubmed: 32234805
Infect Dis Model. 2020 Apr 21;5:293-308
pubmed: 32355904
Science. 2021 Jan 15;371(6526):
pubmed: 33234698
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6146-51
pubmed: 15071187
BMJ. 2020 Dec 15;371:m4750
pubmed: 33323376
BMJ. 2020 Aug 17;370:m3248
pubmed: 32816820
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
Lancet. 2020 Nov 7;396(10261):1525-1534
pubmed: 32979936
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Nat Med. 2020 Oct;26(10):1531-1533
pubmed: 32807936
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32293-32301
pubmed: 33273115
Travel Med Infect Dis. 2020 Jul - Aug;36:101751
pubmed: 32473312
JAMA. 2020 Apr 14;323(14):1341-1342
pubmed: 32125371

Auteurs

Robyn M Stuart (RM)

Department of Mathematical Sciences, University of Copenhagen, Copenhagen, Denmark robyn@math.ku.dk.
Burnet Institute, Melbourne, Victoria, Australia.

Romesh G Abeysuriya (RG)

Burnet Institute, Melbourne, Victoria, Australia.

Cliff C Kerr (CC)

Global Health Division, Institute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, Washington, USA.
School of Physics, University of Sydney, Sydney, New South Wales, Australia.

Dina Mistry (D)

Global Health Division, Institute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, Washington, USA.

Dan J Klein (DJ)

Global Health Division, Institute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, Washington, USA.

Richard T Gray (RT)

The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

Margaret Hellard (M)

Burnet Institute, Melbourne, Victoria, Australia.
Department of Infectious Diseases, The Alfred Hospital, Melbourne, Victoria, Australia.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Doherty Institute and School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.

Nick Scott (N)

Burnet Institute, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH